With new data supporting adjuvant cemiplimab and promising outcomes from neoadjuvant strategies, immunotherapy is reshaping the treatment landscape for high-risk and advanced cutaneous squamous cell carcinoma.
With new data supporting adjuvant cemiplimab and promising outcomes from neoadjuvant strategies, immunotherapy is reshaping the treatment landscape for high-risk and advanced cutaneous squamous cell carcinoma.
With new data supporting...